Brontictuzumab
Chemical compound
- none
- 1447814-75-6
- none
- UNY2TQA40E
- D11229
Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
This drug was developed by OncoMed Pharmaceuticals.
References
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e